A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment
Journal of Cancer Research and Clinical Oncology · 02.10.2024 · 150 (10)
DOI: 10.1007/s00432-024-05945-6 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cancer Research and Clinical Oncology, online erschienen am 02.10.2024. Verfasst von Stefan S Bielack und 8 weiteren Autor:innen. Beteiligte Einrichtung: Paediatrics 5 (Oncology, Haematology, Immunology), Klinikum Stuttgart - Olgahospital, Stuttgart Cancer Centre, Stuttgart, Germany. Hauptthemen laut MEDLINE: Methotrexate, gamma-Glutamyl Hydrolase, Leucovorin. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Charité - Universitätsmedizin Berlin.
Abstract (Originalsprache)
High-dose methotrexate (HDMTX) is used in the treatment of a range of adult and childhood cancers. Although HDMTX can provide effective anti-tumor activity with an acceptable safety profile for most patients, delayed methotrexate elimination (DME) develops in a minority of patients receiving HDMTX and may be accompanied by renal dysfunction and potentially life-threatening toxicity. A panel of European physicians with experience in the use of HDMTX as well as of glucarpidase convened to develop a series of consensus statements to provide practical guidance on the prevention and treatment of DME, including the use of glucarpidase. Robust implementation of supportive measures including hyperhydration and urine alkalinization emerged as critical in order to reduce the risk of DME with HDMTX treatment, with leucovorin rescue critical in reducing the risk of DME complications. Early recognition of DME is important to promptly implement appropriate treatment including, intensified hydration, high-dose leucovorin and, when appropriate, glucarpidase.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Paediatrics 5 (Oncology, Haematology, Immunology), Klinikum Stuttgart - Olgahospital, Stuttgart Cancer Centre, Stuttgart, Germany.
- Service d'Hématologie, Institut Curie, Paris, France.
- School of Medicine, University of Nottingham, Nottingham, UK.
- Department of Neurooncology, IHU, ICM, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, Sorbonne Université, Paris, France.
- Pediatric Oncology and Hematology Service, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
- Department of Haematology, Newcastle Upon Tyne NHS Foundation Trust, and Newcastle University, Newcastle Upon Tyne, UK.
ORCID-Profile: Stefan S Bielack, Carole Soussain, Christopher P Fox, Caroline Houillier, Thais Murciano, Wendy Osborne, Pier Luigi Zinzani, Carmelo Rizzari, Stefan Schwartz
Förderung
- Charité - Universitätsmedizin Berlin
Zitieren
APA
Bielack, S. S., Soussain, C., Fox, C. P., Houillier, C., Murciano, T., Osborne, W., Zinzani, P. L., Rizzari, C., & Schwartz, S. (2024). A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment. Journal of Cancer Research and Clinical Oncology, 150(10). https://doi.org/10.1007/s00432-024-05945-6
Vancouver
Bielack SS, Soussain C, Fox CP, Houillier C, Murciano T, Osborne W, et al. A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment. Journal of Cancer Research and Clinical Oncology. 2024;150(10). doi:10.1007/s00432-024-05945-6
BibTeX
@article{Bielack2024,
author = {Bielack, Stefan S and Soussain, Carole and Fox, Christopher P and Houillier, Caroline and Murciano, Thais and Osborne, Wendy and Zinzani, Pier Luigi and Rizzari, Carmelo and Schwartz, Stefan},
title = {A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2024},
volume = {150},
number = {10},
doi = {10.1007/s00432-024-05945-6}
}
EUVIMED